UK markets closed

Bicycle Therapeutics plc (BCYC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
22.57-0.32 (-1.40%)
At close: 04:00PM EDT
22.57 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 871.49M
Enterprise value 458.32M
Trailing P/E 1.84k
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)21.31
Price/book (mrq)2.45
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-4.11%
S&P500 52-week change 326.27%
52-week high 328.91
52-week low 312.54
50-day moving average 323.80
200-day moving average 320.24

Share statistics

Avg vol (3-month) 3389.75k
Avg vol (10-day) 3292.26k
Shares outstanding 538.07M
Implied shares outstanding 636.71M
Float 8N/A
% held by insiders 11.63%
% held by institutions 1105.92%
Shares short (30 Apr 2024) 42.79M
Short ratio (30 Apr 2024) 46.95
Short % of float (30 Apr 2024) 48.06%
Short % of shares outstanding (30 Apr 2024) 47.33%
Shares short (prior month 28 Mar 2024) 42.54M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-162.40%

Management effectiveness

Return on assets (ttm)-23.04%
Return on equity (ttm)-56.13%

Income statement

Revenue (ttm)41.61M
Revenue per share (ttm)1.07
Quarterly revenue growth (yoy)298.90%
Gross profit (ttm)N/A
EBITDA -173.21M
Net income avi to common (ttm)-168.16M
Diluted EPS (ttm)-4.40
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)457M
Total cash per share (mrq)10.74
Total debt (mrq)38.85M
Total debt/equity (mrq)10.91%
Current ratio (mrq)10.42
Book value per share (mrq)8.37

Cash flow statement

Operating cash flow (ttm)-85.09M
Levered free cash flow (ttm)-46.53M